EGFR and non-small cell lung carcinoma: Among 157 patients received EGFR TKIs, all patients were treated with first-generation EGFR TKI, such as gefitinib, erlotinib, and icotinib, and no patients received osimertinib, the third generation EGFR TKI, which was granted accelerated approval by the China Food and Drug Administration (CFDA) in March 2017 to treat T790M-positive NSCLC patients as second-line therapy.